4//SEC Filing
Adcock Richard 4
Accession 0001326110-23-000010
CIK 0001326110other
Filed
Feb 6, 7:00 PM ET
Accepted
Feb 7, 6:23 PM ET
Size
9.2 KB
Accession
0001326110-23-000010
Insider Transaction Report
Form 4
Adcock Richard
DirectorCEO & President
Transactions
- Exercise/Conversion
Common Stock
2023-02-05+83,333→ 227,774 total - Tax Payment
Common Stock
2023-02-05$4.33/sh−42,192$182,691→ 185,582 total - Exercise/Conversion
Restricted Stock Units
2023-02-05−83,333→ 83,334 total→ Common Stock (83,333 underlying)
Footnotes (3)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock.
- [F2]On February 5, 2023, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on February 3, 2022 was the settlement price used to calculate the shares withheld.
- [F3]Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 83,333 of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 83,334 of the shares shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 5, 2021.
Documents
Issuer
ImmunityBio, Inc.
CIK 0001326110
Entity typeother
Related Parties
1- filerCIK 0001830328
Filing Metadata
- Form type
- 4
- Filed
- Feb 6, 7:00 PM ET
- Accepted
- Feb 7, 6:23 PM ET
- Size
- 9.2 KB